Deutsche Bank analyst James Shin initiated coverage of Bristol Myers with a Hold rating and $55 price target. While the current valuation is attractive and “appears to be a discount,” growth appears to be challenged, the analyst tells investors. Bristol is undergoing a broad portfolio refresh to address multiple patent expirations looming in the back half of the decade, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BMY:
- Bristol Myers Squibb call volume above normal and directionally bullish
- Stifel downgrades Ventyx Biosciences after ‘disappointing’ VTX958 data
- Leerink downgrades Mirati to Market Perform as focus remains on acquisition
- Wells downgrades Ventyx to Equal Weight on ‘major setback’
- Mirati Therapeutics downgraded to Hold on pending buyout at Stifel